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Multiple-Triazole-Resistant Aspergillosis
To the Editor: The use of voriconazole has become common for the management of invasive aspergillosis. However, therapy with voriconazole still sometimes fails, more often because of unresponsive underlying disease than because of resistance of the fungus. Since the first description of itraconazole resistance in Aspergillus fumigatus, 1 three amino acid substitutions in the 14α-sterol demethylase cyp51A gene, which is the target site for azole drugs, have been described. 2 Our laboratory receives fungal isolates for identification and susceptibility testing from throughout the Netherlands. Since 2002, using Clinical and Laboratory Standards Institute methodology, we have observed an increase in the number of A. fumigatus isolates with elevated minimum inhibitory concentrations of voriconazole (2 to >16 mg per liter), itraconazole (>16 mg per liter), the investigational azole ravuconazole (4 to >16 mg per liter), and posaconazole (0.5 to 1.0 mg per liter). Thirteen isolates were cultured from nine patients from six hospitals in the Netherlands (Table 1) . Primary aspergillosis was diagnosed in four patients, and five patients presented with breakthrough invasive aspergillosis.
A new mechanism of resistance, consisting of a Cyp51A amino acid substitution at codon 98 (L98H) together with a tandem repeat in the gene promoter, was found to be responsible for the azole-resistant phenotype. This resistance mechanism was present in 12 of the 13 isolates. Genotyping of the isolates showed no evidence for clonal spread of a single A. fumigatus genotype.
The prevalence of multiple-triazole resistance was compared with a previously conducted nationwide survey of 170 A. fumigatus isolates collected from 114 patients from 21 Dutch hospitals between 1945 and 1998. 4 In this period, no patients with multiple-triazole-resistant isolates were found as compared with 10 of 81 patients in the period since 2002 (P<0.001).
Although the emergence of this new resistance mechanism coincides with the approval of voriconazole, the factors that may explain this phenomenon remain unclear. Four patients became infected with a multiple-triazole-resistant strain during long-term prophylaxis with itraconazole, a drug that has been widely available for clinical use since 1991. The recovery of multiple-triazoleresistant strains in patients who had not been previously treated with azoles suggests that alternative sources of azoles, such as the use of azole compounds in agricultural environments, might play a role. 5 Our observation underscores the need to make an etiologic diagnosis of invasive mold infection Letters to the Editor are considered for publication, subject to editing and abridgment, provided they do not contain material that has been submitted or published elsewhere. Please note the following: •Letters in reference to a Journal article must not exceed 175 words (excluding references) and must be received within 3 weeks after publication of the article. Letters not related to a Journal article must not exceed 400 words. All letters must be submitted over the Internet at http://authors.nejm.org.
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